Symbols

IMNN

Imunon·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Ample Liquidity

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMNN

Imunon, Inc.

A clinical-stage drug development company that develops immunotherapies and other anti-cancer nucleic acid-based therapies to treat cancer

Industry

Biological Technology

Established Date

Listing Date

02/08/2008

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.imunon.com

Security Type

Common stock

Office address

997 Lenox Drive , Suite 100 , Lawrenceville , NJ 08648

Business

Introduction

Imunon, Inc., founded in 1982, is a Delaware corporation. Celsion is a fully integrated oncology drug development company dedicated to the development of innovative cancer treatments, including chemotherapy directing, immunotherapy and RNA- or DNA-based therapeutic combinations. The company's lead program is ThermoDox, a patented heat-activated liposomal encapsulation of doxorubicin, which is currently in Phase III clinical trials for the treatment of primary liver cancer (OPTIMA study) and Phase II clinical trials for the recurrence of chest wall breast cancer (DIGNITY study). Its pipeline also includes GEN-1 (formerly EGEN-001), DNA-based immunotherapy for ovarian cancer and local treatment for brain cancer. The company has three platform technologies for therapeutic development for those hard-to-treat cancers, new nucleic acid-based immunotherapies and other anticancer DNA or RNA therapies, including TheraPlas and TheraSilence. Beginning in the first half of 2014, the product ThermoDox is undergoing a Phase III clinical trial for primary liver cancer (OPTIMA study) and a Phase II clinical trial for recurrent chest wall breast cancer (DIGNITY study).

Earnings Call

Q1/2025

Estimate EPS-0.36

Actual EPS-0.28

Estimate Revenue--

Actual Revenue0

Imunon's Q1 2025: Key Contradictions in Phase III Trial Design, Enrollment, and Manufacturing

May 20,2025 09:40·
Earnings Decrypt

Q2/2025

Estimate EPS-4.99

Actual EPS-2.15

Estimate Revenue--

Actual Revenue0

Imunon's Q2 2025 Earnings Call: Key Contradictions in Phase III Trials and Partnership Strategies

Aug 05,2025 01:33·
Earnings Decrypt

Company Financials

EPS

IMNN has released its 2025 Q3 earnings. EPS was reported at -1.16, versus the expected -1.82, beating expectations. The chart below visualizes how IMNN has performed over recent quarters, highlighting trends in earnings surprises.